Ranking Alexa Global: # 7,495,498
Server:Apache/2.4.18 (Ubunt...
The main IP address: 194.33.13.55,Your server United Kingdom,Landbeach ISP:Bridge Fibre Limited TLD:com CountryCode:GB
The description :transforming personalised medicine with leading microbiome science...
This report updates in 28-Jun-2018
Created Date: | 2007-10-30 |
Changed Date: | 2018-05-14 |
Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host microbiotica.com. Currently, hosted in United Kingdom and its service provider is Bridge Fibre Limited .
Latitude: | 52.26448059082 |
Longitude: | 0.16225999593735 |
Country: | United Kingdom (GB) |
City: | Landbeach |
Region: | England |
ISP: | Bridge Fibre Limited |
HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache/2.4.18 (Ubuntu) containing the details of what the browser wants and will accept back from the web server.
Content-Length: | 4126 |
Content-Encoding: | gzip |
Set-Cookie: | CMSSESSID788bde3c0a5f=e6km3h4o19r7u4a3e4p67n5lu7; path=/ |
Expires: | Thu, 19 Nov 1981 08:52:00 GMT |
Vary: | Accept-Encoding |
Keep-Alive: | timeout=5, max=100 |
Server: | Apache/2.4.18 (Ubuntu) |
Connection: | Keep-Alive |
Pragma: | no-cache |
Cache-Control: | no-store, no-cache, must-revalidate |
Date: | Thu, 28 Jun 2018 14:16:45 GMT |
Content-Type: | text/html; charset=utf-8 |
soa: | ns-cloud-b1.googledomains.com. cloud-dns-hostmaster.google.com. 1 21600 3600 259200 300 |
txt: | "v=spf1 include:spf.protection.outlook.com -all" |
ns: | ns-cloud-b1.googledomains.com. ns-cloud-b2.googledomains.com. ns-cloud-b3.googledomains.com. ns-cloud-b4.googledomains.com. |
ipv4: | IP:194.33.13.55 ASN:51055 OWNER:BRIDGEP-AS, GB Country:GB |
mx: | MX preference = 0, mail exchanger = microbiotica-com.mail.protection.outlook.com. |
company the microbiome platform pipeline board of directors leadership team news & events careers contact us transforming personalised medicine with leading microbiome science microbiotica identifies gut bacteria linked to phenotype with unprecedented precision in order to discover and develop live bacterial therapeutics and biomarkers company microbiotica was launched in december 2016 with the aim of creating a global leader to exploit the leading microbiome science built at the wellcome trust sanger institute . the company retains a close association with the sanger institute and its founders and is based at the wellcome genome campus, cambridge uk. the microbiome the human body is host to trillions of microbes, comprising several hundred species per person residing mainly in the gastrointestinal tract. they are generally in a symbiotic relationship, impart protective functions to the gut, and regulate immunological, metabolic and neuronal functions throughout the body. disruptions to the microbiome are implicated in a host of disorders, for example ibd, ibs, metabolic disease, cancer and parkinson’s, and it is now clear that gut microbiota regulate the response to cancer immunotherapies. thus the microbiome represents a major new opportunity in the discovery of medicines and biomarkers. the biggest barrier to this has been the inability to precisely identify a patient’s bacteria and then to undertake functional studies in order to understand the biology. platform the microbiotica platform is based on world leading tools developed at the wellcome trust sanger institute that unblock the barriers to discovery. these are founded on a unique capability to culture, characterise and phenotype the majority of a patient’s gut bacteria, enabling precise association of bacteria to function for the first time. they also include the leading microbiota culture collection and reference genome database which provide resources for precise metagenomic analysis and functional studies, and humanised in vitro and in vivo models of disease. using these tools microbiotica starts programs with deep analysis of samples from clinical trials and progresses medicines and biomarkers through lab testing back into the clinic. pipeline microbiotica has programs in ibd, immune-oncology and clostridium difficile , developing medicines and biomarkers based on microbiota. these programs start with deep metagenomic and culture-based analysis of patient samples linked to phenotype before testing of candidate bacteria in advanced human in vitro and in vivo models. the company’s c. difficile defined live bacterial therapeutic asset will be used to validate our manufacturing and delivery technologies. board of directors sam williams investor director, chair -- robert tansley investor director -- john shields non-executive director -- mike romanos co-founder and ceo -- trevor lawley co-founder and cso -- leadership team mike romanos co-founder and ceo -- trevor lawley co-founder and cso -- nigel crockett vp business development -- rowena gardner vp operations and company secretary -- thomas sandal vp preclinical development -- nan worrell vp clinical development -- gordon dougan frs co-founder -- latest news microbiotica collaborates with university of adelaide to develop a novel microbial therapy for ulcerative colitis cambridge, uk, 18 june 2018 – microbiotica, a leading player in microbiome-based therapeutics, today announced that it has entered into an agreement... read more... microbiotica enters into microbiome collaboration with genentech strategic collaboration for microbiome biomarker signatures and therapeutic discovery based on genentech’s inflammatory bowel disease... read more... microbiotica to present at top microbiome conferences cambridge, uk, 22 may 2018 – microbiotica, a leading player in microbiome-based therapeutics, announces that it will present at leading microbiome... read more... contact us name email message microbiotica limited biodata innovation centre wellcome genome campus cambridge cb10 1dr find us on linkedin [email protected] © microbiotica 2018
https://www.microbiotica.com/news/14/58/microbiotica-to-present-at-top-microbiome-conferences.html
https://www.microbiotica.com/contact-us
https://www.microbiotica.com/home#company
https://www.microbiotica.com/about#bod
https://www.microbiotica.com/about#53
https://www.microbiotica.com/about#52
https://www.microbiotica.com/about#51
https://www.microbiotica.com/about#56
https://www.microbiotica.com/about#55
https://www.microbiotica.com/about#54
https://www.microbiotica.com/news-events
https://www.microbiotica.com/about#62
https://www.microbiotica.com/about#leadership
https://www.microbiotica.com/careers
https://www.microbiotica.com/home#platform
sanger.ac.uk
Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;
Domain Name: MICROBIOTICA.COM
Registry Domain ID: 1308114426_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.meshdigital.com
Registrar URL: http://www.meshdigital.com
Updated Date: 2018-05-14T13:14:44Z
Creation Date: 2007-10-30T13:43:04Z
Registry Expiry Date: 2019-10-30T13:43:04Z
Registrar: Mesh Digital Limited
Registrar IANA ID: 1390
Registrar Abuse Contact Email:
Registrar Abuse Contact Phone:
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: NS-CLOUD-B1.GOOGLEDOMAINS.COM
Name Server: NS-CLOUD-B2.GOOGLEDOMAINS.COM
Name Server: NS-CLOUD-B3.GOOGLEDOMAINS.COM
Name Server: NS-CLOUD-B4.GOOGLEDOMAINS.COM
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2018-06-28T14:16:30Z <<<
For more information on Whois status codes, please visit https://icann.org/epp
NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.
TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.
The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.
REGISTRAR Mesh Digital Limited
SERVERS
SERVER com.whois-servers.net
ARGS domain =microbiotica.com
PORT 43
TYPE domain
DOMAIN
NAME microbiotica.com
CHANGED 2018-05-14
CREATED 2007-10-30
STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
NSERVER
NS-CLOUD-B1.GOOGLEDOMAINS.COM 216.239.32.107
NS-CLOUD-B2.GOOGLEDOMAINS.COM 216.239.34.107
NS-CLOUD-B3.GOOGLEDOMAINS.COM 216.239.36.107
NS-CLOUD-B4.GOOGLEDOMAINS.COM 216.239.38.107
REGISTERED yes
The following list shows you to spelling mistakes possible of the internet users for the website searched .